374 related articles for article (PubMed ID: 11359807)
1. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
Ryan SO; Turner MS; GariƩpy J; Finn OJ
Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
[TBL] [Abstract][Full Text] [Related]
3. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
Stern BV; Boehm BO; Tary-Lehmann M
J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220
[TBL] [Abstract][Full Text] [Related]
5. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
6. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.
Pejawar-Gaddy S; Rajawat Y; Hilioti Z; Xue J; Gaddy DF; Finn OJ; Viscidi RP; Bossis I
Cancer Immunol Immunother; 2010 Nov; 59(11):1685-96. PubMed ID: 20652244
[TBL] [Abstract][Full Text] [Related]
7. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
9. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
[TBL] [Abstract][Full Text] [Related]
11. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
12. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.
Ding C; Wang L; Marroquin J; Yan J
Blood; 2008 Oct; 112(7):2817-25. PubMed ID: 18669871
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
14. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.
Xia J; Tanaka Y; Koido S; Liu C; Mukherjee P; Gendler SJ; Gong J
J Immunol; 2003 Feb; 170(4):1980-6. PubMed ID: 12574367
[TBL] [Abstract][Full Text] [Related]
15. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.
Turner MS; Cohen PA; Finn OJ
J Immunol; 2007 Mar; 178(5):2787-93. PubMed ID: 17312122
[TBL] [Abstract][Full Text] [Related]
16. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.
Akporiaye ET; Bradley-Dunlop D; Gendler SJ; Mukherjee P; Madsen CS; Hahn T; Besselsen DG; Dial SM; Cui H; Trevor K
Vaccine; 2007 Sep; 25(39-40):6965-74. PubMed ID: 17707958
[TBL] [Abstract][Full Text] [Related]
18. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
[TBL] [Abstract][Full Text] [Related]
19. Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes.
Farkas AM; Marvel DM; Finn OJ
J Immunol; 2013 Apr; 190(7):3319-27. PubMed ID: 23420890
[TBL] [Abstract][Full Text] [Related]
20. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]